Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) Receives $9.46 Average Price Target from Analysts

Shares of Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) have been assigned a consensus rating of “Hold” from the twelve research firms that are covering the stock, MarketBeat Ratings reports. One analyst has rated the stock with a sell recommendation, seven have issued a hold recommendation and four have given a buy recommendation to the company. The average twelve-month target price among brokerages that have covered the stock in the last year is $9.28.

Several research analysts recently commented on the stock. Guggenheim assumed coverage on shares of Maravai LifeSciences in a research note on Thursday, December 19th. They issued a “neutral” rating on the stock. Baird R W downgraded shares of Maravai LifeSciences from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, February 26th. Robert W. Baird downgraded shares of Maravai LifeSciences from an “outperform” rating to a “neutral” rating and reduced their price target for the stock from $9.00 to $3.00 in a research note on Wednesday, February 26th. Wolfe Research assumed coverage on shares of Maravai LifeSciences in a research note on Thursday, November 14th. They issued a “peer perform” rating on the stock. Finally, The Goldman Sachs Group downgraded shares of Maravai LifeSciences from a “neutral” rating to a “sell” rating and reduced their price target for the stock from $7.00 to $4.25 in a research note on Thursday, December 5th.

Insiders Place Their Bets

In other news, General Counsel Kurt Oreshack sold 25,000 shares of the firm’s stock in a transaction dated Friday, January 31st. The shares were sold at an average price of $5.03, for a total value of $125,750.00. Following the sale, the general counsel now directly owns 167,618 shares in the company, valued at approximately $843,118.54. This trade represents a 12.98 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 0.63% of the stock is owned by company insiders.

Institutional Trading of Maravai LifeSciences

A number of institutional investors have recently modified their holdings of the company. Creative Planning boosted its holdings in shares of Maravai LifeSciences by 4.4% in the 3rd quarter. Creative Planning now owns 44,943 shares of the company’s stock valued at $373,000 after buying an additional 1,881 shares in the last quarter. SG Americas Securities LLC boosted its holdings in shares of Maravai LifeSciences by 7.3% in the 4th quarter. SG Americas Securities LLC now owns 33,046 shares of the company’s stock valued at $180,000 after buying an additional 2,239 shares in the last quarter. China Universal Asset Management Co. Ltd. boosted its holdings in shares of Maravai LifeSciences by 10.5% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 30,076 shares of the company’s stock valued at $164,000 after buying an additional 2,851 shares in the last quarter. Kornitzer Capital Management Inc. KS boosted its holdings in shares of Maravai LifeSciences by 0.7% in the 3rd quarter. Kornitzer Capital Management Inc. KS now owns 519,890 shares of the company’s stock valued at $4,320,000 after buying an additional 3,725 shares in the last quarter. Finally, Performa Ltd US LLC boosted its holdings in shares of Maravai LifeSciences by 614.3% in the 4th quarter. Performa Ltd US LLC now owns 5,000 shares of the company’s stock valued at $27,000 after buying an additional 4,300 shares in the last quarter. 50.25% of the stock is currently owned by institutional investors.

Maravai LifeSciences Trading Up 10.9 %

Shares of MRVI opened at $2.96 on Friday. Maravai LifeSciences has a twelve month low of $2.63 and a twelve month high of $11.56. The company has a market cap of $747.48 million, a P/E ratio of -1.80 and a beta of -0.08. The company has a current ratio of 10.74, a quick ratio of 9.94 and a debt-to-equity ratio of 0.89. The company’s fifty day simple moving average is $4.59 and its 200-day simple moving average is $6.26.

About Maravai LifeSciences

Maravai LifeSciences Holdings, Inc, a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases worldwide. The company’s products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species.